An update on belimumab for the treatment of lupus

被引：13
作者：
Thanou-Stavraki, Aikaterini [1 ]
Sawalha, Amr H. [1 ,2 ,3 ]
机构：
[1] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA
[2] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA
[3] Oklahoma Med Res Fdn, Arthrit & Clin Immunol Program, 825 NE 13th St,MS 24, Oklahoma City, OK 73104 USA
来源：
BIOLOGICS-TARGETS & THERAPY | 2011年 / 5卷
关键词：
B lymphocyte stimulator; lupus erythematosus; belimumab;
D O I：
10.2147/BTT.S13804
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
B-lymphocyte stimulator (BLyS), a homeostatic factor for B-cell differentiation and survival, has a major role in B-cell expansion and autoreactivity that characterize systemic lupus erythematosus (SLE). Belimumab, a BLyS-specific inhibitor, has shown promising evidence of efficacy in several preclinical and clinical studies in SLE. Two recent large randomized controlled trials yielded a significant positive effect of the drug compared to placebo in patients with active disease. In this review, we discuss basic aspects of B-cell and BLyS biology in SLE and summarize the evidence supporting a role of belimumab in SLE, from animal studies to phase III clinical trials.
引用
收藏
页码：33 / 43
页数：11
相关论文
共 44 条
  • [1] [Anonymous], 2006, GUID IND SYST LUP ER
  • [2] Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator
    Baker, KP
    Edwards, BM
    Main, SH
    Choi, GH
    Wager, RE
    Halpern, WG
    Lappin, PB
    Riccobene, T
    Abramian, D
    Sekut, L
    Sturm, B
    Poortman, C
    Minter, RR
    Dobson, CL
    Williams, E
    Carmen, S
    Smith, R
    Roschke, V
    Hilbert, DM
    Vaughan, TJ
    Albert, VR
    [J]. ARTHRITIS AND RHEUMATISM, 2003, 48 (11): : 3253 - 3265
  • [3] EULAR points to consider for conducting clinical trials in systemic lupus erythematosus: literature based evidence for the selection of endpoints
    Bertsias, G. K.
    Ioannidis, J. P. A.
    Boletis, J.
    Bombardieri, S.
    Cervera, R.
    Dostal, C.
    Font, J.
    Gilboe, I. M.
    Houssiau, F.
    Huizinga, T.
    Isenberg, D.
    Kallenberg, C. G. M.
    Khamashta, M.
    Piette, J. C.
    Schneider, M.
    Smolen, J.
    Sturfelt, G.
    Tincani, A.
    van Vollenhoven, R.
    Boumpas, D. T.
    Gordon, C.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (04) : 477 - 483
  • [4] CHATHAM W, 2008, ANN RHEUM DIS, V67, P217
  • [5] Chatham W, 2010, ANN RHEUM DIS S3, V69, P147
  • [6] Chatham W, 2010, ARTHRITIS RHEUM S10, V62, P192
  • [7] Cheema GS, 2001, ARTHRITIS RHEUM-US, V44, P1313, DOI 10.1002/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO
  • [8] 2-S
  • [9] B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels
    Collins, CE
    Gavin, AL
    Migone, TS
    Hilbert, DM
    Nemazee, D
    Stohl, W
    [J]. ARTHRITIS RESEARCH & THERAPY, 2006, 8 (01)
  • [10] Abnormalities of B cell subsets in patients with systemic lupus erythematosus
    Doerner, Thomas
    Jacobi, Annett M.
    Lee, Jisoo
    Lipsky, Peter E.
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 2011, 363 (02) : 187 - 197
12345